Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    M2i Group Roflumilast

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Roflumilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 158,313Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Arcutis Announces Promotions on Executive Management Team
    Arcutis Announces Promotions on Executive Management Team

    03 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/03/2990547/0/en/Arcutis-Announces-Promotions-on-Executive-Management-Team.html

    GLOBENEWSWIRE
    03 Dec 2024
    Share Share
    Arcutis’ ZORYVE® Awarded Best Eczema Treatment by Glamour
    Arcutis’ ZORYVE® Awarded Best Eczema Treatment by Glamour

    13 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/13/2980227/0/en/Arcutis-ZORYVE-roflumilast-Awarded-Best-Eczema-Treatment-by-Glamour.html

    GLOBENEWSWIRE
    13 Nov 2024
    Share Share
    Arcutis Drug Recieves Canada Approval to Treat Seborrheic Dermatitis
    Arcutis Drug Recieves Canada Approval to Treat Seborrheic Dermatitis

    19 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/18/2965499/0/en/Arcutis-Announces-Health-Canada-Approval-of-ZORYVE-Roflumilast-Foam-0-3-to-Treat-Seborrheic-Dermatitis-in-Individuals-9-Years-of-Age-and-Older.html

    GLOBENEWSWIRE
    19 Oct 2024
    Share Share
    Zoryve Cream 0.15% Shows Improvement in Atopic Dermatitis Patients
    Zoryve Cream 0.15% Shows Improvement in Atopic Dermatitis Patients

    24 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2952682/0/en/New-Data-Shows-ZORYVE-Roflumilast-Cream-0-15-Provided-Consistent-Improvement-of-Atopic-Dermatitis-in-Individuals-With-Diverse-Skin-Types.html

    GLOBENEWSWIRE
    24 Sep 2024
    Share Share
    FDA Accepts Arcutis’ Application for ZORYVE Foam for Scalp Psoriasis
    FDA Accepts Arcutis’ Application for ZORYVE Foam for Scalp Psoriasis

    24 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/24/2952078/0/en/FDA-Accepts-Arcutis-Supplemental-New-Drug-Application-for-ZORYVE-roflumilast-Foam-for-the-Treatment-of-Scalp-and-Body-Psoriasis-in-Adults-and-Adolescents-Ages-12-and-Over.html

    GLOBENEWSWIRE
    24 Sep 2024
    Share Share
    Arcutis Announces Positive Results For Roflumilast Cream In Children
    Arcutis Announces Positive Results For Roflumilast Cream In Children

    28 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/28/2936957/0/en/Arcutis-Announces-Positive-Long-Term-Results-of-Roflumilast-Cream-0-05-Show-Durable-and-Improved-Efficacy-Over-Time-and-Favorable-Safety-Profile-in-Treatment-of-Children-Aged-2-to-.html

    GLOBENEWSWIRE
    28 Aug 2024
    Share Share